Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size


Anabolic β2-adrenoceptor (β2-AR) agonists have been proposed as therapeutics for treating muscle wasting but concerns regarding possible off-target effects have hampered their use. We investigated whether β2-AR-mediated signalling could be modulated in skeletal muscle via gene delivery to the target tissue, thereby avoiding the risks of β2-AR agonists. In mice, intramuscular administration of a recombinant adeno-associated virus-based vector (rAAV vector) expressing the β2-AR increased muscle mass by >20% within 4 weeks. This hypertrophic response was comparable to that of 4 weeks’ treatment with the β2-AR agonist formoterol and was not ablated by mTOR inhibition. Increasing expression of inhibitory (Gαi2) and stimulatory (GαsL) G-protein subunits produced minor atrophic and hypertrophic changes in muscle mass, respectively. Furthermore, Gαi2 over-expression prevented AAV:β2-AR mediated hypertrophy. Introduction of the non-muscle Gαs isoform, GαsXL elicited hypertrophy comparable to that achieved by AAV:β2-AR. Moreover, GαsXL gene delivery was found to be capable of inducing hypertrophy in the muscles of mice lacking functional β1- and β2-ARs. These findings demonstrate that gene therapy-based interventions targeting the β2-AR pathway can promote skeletal muscle hypertrophy independent of ligand administration and highlight novel methods for potentially modulating muscle mass in settings of disease.


Over 800 G-protein coupled receptor (GPCR) variants are encoded by the human genome1. As transmembrane receptors, the GPCRs represent the target of nearly one-third of all pharmaceuticals developed to date2. One of the best characterized GPCRs in skeletal muscle is the β2-adrenoceptor (β2-AR)3. In vivo, endogenous catecholamines such as adrenaline activate skeletal muscle β2-ARs to promote receptor interaction with stimulatory (Gαs) and inhibitory (Gαi) G-proteins4. The activation of these intracellular effectors differentially regulates adenylyl cyclase (AC) activity and subsequent cAMP accumulation, which impacts on several cellular mechanisms that influence the muscle phenotype5. Chronic stimulation of skeletal muscle β2-ARs through administration of β2-AR agonists such as clenbuterol, fenoterol and formoterol has well-characterized anabolic consequences, resulting in increased muscle mass and force-producing capacity6,7. Anabolism of skeletal muscle following β2-AR agonist administration has been associated with increased protein synthesis via stimulation of the Akt-mTOR-S6 kinase signalling axis8,9. However, β2-AR agonist administration can also attenuate protein degradation by repressing transcription of the muscle-specific E3 ubiquitin ligases Murf1 and Atrogin-1 and Ca2+-dependent proteases10,11,12.

Because sustained stimulation of β2-AR in skeletal muscle supports anabolic and anti-catabolic processes, synthetic β2-AR agonists have been investigated as potential therapeutics to combat the loss of muscle mass and force-producing capacity associated with conditions such as neurogenic muscle atrophy9,13,14, muscular dystrophy15,16,17, sarcopenia6,18 and cancer cachexia7,19,20. However, the expression of β2-ARs in other cell types has prompted concerns about the risks of off-target effects arising from long-term systemic administration of β2-AR agonists. Consequently, clinical application of these compounds for muscle wasting has remained limited. We investigated whether stimulation of β2-AR signalling that promotes skeletal muscle hypertrophy might be achievable by means that circumvent the potential off-target effects of β2-AR agonists. Specifically, we hypothesised that administering gene therapy-based interventions to alter the expression of β2-AR pathway components could promote skeletal muscle growth independent of β2-AR agonist administration. This rationale was based on the emerging development of recombinant adeno-associated virus-based vectors (rAAV vectors) as tools for therapeutic gene delivery, owing to their propensity for achieving efficacious and targeted delivery of transgenes to the skeletal muscles of mammals21,22, including humans23,24, that can sustain transgene expression for over a decade following a single treatment24.

Our studies identified that β2-AR gene delivery using rAAV vectors can promote skeletal muscle hypertrophy in mice without administration of synthetic β2-AR agonists. Additionally, we observed that increasing the expression of specific G-protein subunits could exert hypertrophic and atrophic effects in skeletal muscle independent of ligand administration. These studies introduce targeted gene delivery as a new strategy for manipulating the β2-AR signalling pathway without administering β2-AR agonists, to promote skeletal muscle hypertrophy.


β2-AR gene delivery promotes skeletal muscle hypertrophy and protein synthesis

To determine the effects of increasing β2-AR abundance in muscle fibres, we used adeno-associated virus-based vectors encoding the β2-AR (AAV:β2-AR) or a gene-less cassette (control) to transduce the tibialis anterior (TA) hind-limb muscles of male eight-week-old C57Bl/6 mice. Optimisation of vector doses established that injection of muscles with 1 × 1010 AAV:β2-AR vector genomes (vg) produced a 22% increase in muscle mass within 28 days of vector administration, which was maintained for at least 84 days after vector delivery (the longest time point examined) (Fig. 1a). Cross-sections of muscles immunolabelled for β2-AR and laminin confirmed widespread expression of β2-AR on the sarcolemma of transduced muscle fibres (Fig. 1b) and an increase in the diameter of muscle fibres in treated muscles (Fig. 1c). Muscles administered AAV:β2-AR exhibited increased rates of protein synthesis as measured by acute puromycin incorporation25 (Fig. 1d,e). To assess whether AAV:β2-AR administration altered the muscle fibre type distribution, sections of treated TA muscles were examined via histochemical reaction to estimate succinate dehydrogenase (SDH) activity and immunolabelled for prevalence of the myosin type IIa isoform. Muscles examined four weeks after administration of AAV:β2-AR or control vector did not exhibit a difference in the proportion of fibres expressing the type IIa myosin heavy chain isoform, or the activity of SDH (Supplementary Fig. S1).

Figure 1

β2-AR gene delivery promotes skeletal muscle hypertrophy and protein synthesis.

(a) TA muscle mass examined 3, 7, 14, 28 and 84 days after AAV:β2-AR administration. (b) Representative immunofluorescent images of β2-AR density (shown in green) at the myofibre membrane (shown in red) in control and AAV:β2-AR treated muscles four weeks post-injection (scale bar = 50 μm). Representative H&E images of TA muscle cross-sections four weeks after administration of control vector or AAV:β2-AR (scale bar = 50 μm). (c) Minimum Feret’s diameter measurements of TA muscle fibres examined four weeks after administration of control vector or AAV:β2-AR. (d,e) Representative western blots and densitometry showing puromycin incorporation in TA muscles four weeks after vector administration. (f) TA muscle mass four weeks after administration of control vector or AAV:β2-AR, or four weeks after 28 consecutive days of vehicle or formoterol administration (muscle mass is expressed relative to tibial bone length to account for differences in body mass caused by systemic effects of formoterol administration). Data are mean ± SEM. n = 3–10 mice/group. *p < 0.05.

To determine if the magnitude of hypertrophy induced via administration of AAV:β2-AR was comparable to that achieved by treating muscles with anabolic β2-AR agonists, additional cohorts of mice were administered AAV:β2-AR, or daily injections of formoterol (100 μg/kg) for 28 days. We observed that a single administration of AAV:β2-AR and 28 consecutive days of formoterol administration produced comparable increases in muscle mass (Fig. 1f, normalised relative to tibial bone length rather than body mass to account for the effect of changes in lean mass in mice receiving formoterol).

Muscle hypertrophy induced by β2-AR gene delivery is not inhibited by rapamycin

As repeated administration of anabolic β2-AR agonists has been reported to promote skeletal muscle growth via signalling dependent on the activation of mTOR, we investigated whether hypertrophy as a consequence of AAV:β2-AR administration was also associated with mTOR-driven processes. Western blot analysis of TA muscles examined 14 days after administration of AAV:β2-AR or control vector revealed a significant increase in phosphorylation of S6RP but not the upstream regulators Akt and mTOR (Supplementary Fig. S2). Additional mice administered AAV:β2-AR were treated with 28 daily injections of rapamycin, an inhibitor of mTOR, to further test whether mTOR activity is necessary to achieve muscle hypertrophy associated with increased β2-AR expression. Increases in muscle mass and myofibre diameter as a consequence of transducing muscles with AAV:β2-AR did not differ between animals receiving rapamycin or vehicle for 28 days (Fig. 2a and Supplementary Fig. S3). Furthermore, whereas administration of AAV:β2-AR increased phosphorylation of P70S6K and S6RP, rapamycin administration inhibited phosphorylation of these two proteins and 4EBP1 (Fig. 2b and Supplementary Fig. S3), thereby confirming the bioactivity of the rapamycin regimen used.

Figure 2

Muscle hypertrophy induced by β2-AR gene delivery is not inhibited by Rapamycin.

(a) TA muscle mass four weeks post control vector or AAV:β2-AR injection and daily administration of vehicle or rapamycin. (b) Representative western blots indicating phosphorylated and total levels of 4EBP1, P70S6K, S6RP and GAPDH as a loading control. (n = 5 mice/group) Data are mean ± SEM. *p < 0.05.

GαsL and Gαi2 gene delivery have opposing effects on TA muscle mass

As β2-adrenoceptors utilise stimulatory (Gαs) and inhibitory (Gαi) G-proteins to propagate intracellular signalling, we investigated whether treating the TA muscles of mice with AAV vectors that increase expression of either GαsL or Gαi2 affected muscle mass. Injection of TA muscles with AAV:GαsL four weeks prior to examination increased mass by 8% (Fig. 3a), whereas administration of AAV:Gαi2 was associated with a 6% decrease in muscle mass (Fig. 3b). Expression of FLAG-tagged GαsL and Gαi2 proteins was confirmed by Western blot (Fig. 3c,d respectively). As our data showed Gαi2 to be a negative regulator of muscle mass, we investigated whether increased expression of Gαi2 could attenuate the anabolic effects of β2-AR gene delivery. Cohorts of mice received intramuscular injections of AAV:β2-AR in combination with AAV:Gαi2 or control vector. Consistent with effects reported in Fig. 1, mice administered AAV:β2-AR and control vector demonstrated TA muscle hypertrophy (Fig. 4a). However, co-administration of AAV:Gαi2 completely prevented the anabolic effects of AAV:β2-AR administration (Fig. 4a). To validate this observation, additional mice received bilateral TA muscle injections of AAV:β2-AR in combination with AAV:Gαi2 or control vector. Four weeks after vector administration, TA muscles administered AAV:β2-AR with control vector exhibited a 20% increased mass compared with contralateral muscles co-administered AAV:β2-AR with AAV:Gαi2 (Fig. 4b). Immunolabelling of muscles confirmed comparable expression of β2-AR between treatment conditions (Fig. 4c).

Figure 3

GαsL and Gαi2 gene delivery have opposing effects on TA muscle mass.

(a) TA muscle mass four weeks after administration of control vector or AAV:GαsL. (b) TA muscle mass four weeks after administration of control vector or AAV:Gαi2. (c) Western blot analysis of FLAG-tagged GαsL in TA muscles injected with AAV:GαsL. (d) Western blot analysis of FLAG-tagged Gαi2 in TA muscles injected with AAV:Gαi2. Data are mean ± SEM. n = 6–7 mice/group. *p < 0.05.

Figure 4

Gαi2 gene delivery inhibits the anabolic effects of β2-AR gene delivery.

(a) TA muscle mass four weeks after administration of control vector, AAV:β2-AR or AAV:β2-AR and AAV:Gαi2. (b) TA muscle mass four weeks after administration of AAV:β2-AR with control vector or AAV:β2-AR with AAV:Gαi2. (c) Representative immunofluorescent images confirming β2-AR over-expression (shown in green) and nuclei (shown in blue) four weeks after vector administration (scale bar = 50 μm). Data are mean ± SEM. n = 6 mice/group. *p < 0.05.

GαsXL gene delivery promotes muscle hypertrophy independent of β1- and β2- adrenoceptors

The extra-large isoform of Gαs, GαsXL, is predominantly expressed in neurons and has been reported to promote increased cAMP activity compared to GαsL in a cell culture model of β2-AR activation26,27. Reasoning that ectopic expression of GαsXL in skeletal muscle could confer greater effects on muscle mass than those achieved via GαsL gene delivery, we examined the effects of administering AAV:GαsXL to the TA muscles of C57Bl6 mice. Muscles examined 28 days after administration of AAV:GαsXL exhibited a 27% increase in mass (Fig. 5a) and a significant increase in myofibre diameter (Fig. 5b) compared to contralateral muscles receiving control vector. Administration of AAV:GαsXL was also associated with an increased proportion of muscle fibres expressing the type IIa myosin heavy chain isoform, although no accompanying significant change in SDH activity was observed (Supplementary Fig. S4). Consistent with the stimulatory effects of AAV:β2-AR administration upon protein synthesis (reported in Fig. 1d), the muscles of wild-type mice treated with AAV:GαsXL also demonstrated markedly increased rates of protein synthesis, as estimated from puromycin incorporation (Fig. 5e,f). To determine whether muscle hypertrophy associated with AAV:GαsXL administration was dependent on β-AR activity, we administered AAV:GαsXL to mice lacking functional β1- and β2-ARs (β12mut mice)28,29. Four weeks after administration of AAV:GαsXL to β12mut mice, treated TA muscles exhibited a 35% increased mass (Fig. 5a) and significantly increased muscle fibre diameter (Fig. 5b,c), compared with contralateral muscles administered control vector. Comparable expression of GαsXL was confirmed in the treated muscles of C57Bl6 and β12mut mice by western blot probing for flag-tagged GαsXL (Fig. 5d).

Figure 5

GαsXL gene delivery promotes muscle hypertrophy independent of β1- and β2- adrenoceptors.

(a) TA muscle mass four weeks after administration of control vector or AAV:GαsXL to C57Bl6 or β12mut mice. (b) Minimum Feret’s diameter measurements of TA muscle fibres from C57Bl6 and β12mut mice treated with control vector or AAV:GαsXL. (c) Representative H&E images of TA muscle cross-sections examined four weeks after vector administration (scale bar = 50 μm). (d) Western blot confirming the presence of flag tagged GαsXL in treated muscles. (e,f) Western blot and densitometry displaying puromycin incorporation in TA muscles four weeks post treatment. Data points are portrayed together with mean ± SEM. n = 3–6 mice/group. *p < 0.05. p = 0.05.


Although synthetic β2-AR agonists exert anabolic and anti-catabolic effects on mammalian skeletal muscles, their clinical application for muscle wasting has been limited by concerns regarding potential off-target effects30,31,32. Our findings demonstrate a novel method of stimulating β2-AR signalling in muscle fibres, based on the use of recombinant AAV vectors to deliver β2-AR or Gαs expression constructs. As recombinant viral vectors can be configured to achieve tissue-specific transgene delivery and expression by combining the cell-selective tropism of vectors with cell-specific transcription/translation control elements33,34, muscle-directed gene delivery may hold potential as a strategy for manipulating the β2-adrenergic network without the need to repeatedly administer potent β2-AR agonists. The benefits of such an approach could provide the means to effectively promote anabolic signalling in the target tissue (i.e. skeletal muscle), while minimising the potential for incurring off-target effects in other tissues.

Using rAAV vectors to enhance β2-AR expression in mouse limb muscles promoted increases in myofibre size and augmented protein synthesis. The hypertrophic effects of AAV:β2-AR administration were comparable in magnitude to those achieved with repeated administration of the potent β2-AR agonist formoterol. We did not find evidence that activation of mTOR was required to support muscle hypertrophy induced by β2-AR gene delivery, which contrasts with reports of β2-AR agonist-induced skeletal muscle hypertrophy requiring mTOR signalling9. As myogenic cells can elicit an anabolic response downstream of the β2-AR via the PKC/GSK3β signalling axis35, hypertrophy as a result of AAV:β2-AR administration could utilise similar mechanisms. These observations point to other possible advantages of developing skeletal-muscle-directed gene delivery as an alternative method for manipulating β2-adrenergic signalling in vivo. Further research is warranted to more comprehensively examine the similarities and differences between drug- and gene-based interventions targeting this signalling system in striated muscle.

Having established that β2-AR gene delivery can stimulate skeletal muscle hypertrophy, we investigated whether β2-AR-mediated effects could be potentiated by increasing the abundance of specific Gα protein subunits operating as signalling substrates for the β2-AR. Increasing expression of GαsL promoted a modest hypertrophic effect compared with AAV:β2-AR administration. Broadly, this stimulatory role of Gαs is consistent with earlier work demonstrating that muscle mass is reduced in Gαs knockout mice36. In contrast, increasing expression of Gαi2 alone produced muscle atrophy and more significantly, co-delivery of AAV:Gαi2 with AAV:β2-AR completely prevented the hypertrophic effects of β2-AR gene delivery. These findings are consistent with the possibility that Gαi2 possesses comparatively greater (relative to Gαs) affinity for interaction with the β2-AR, or that increased abundance of Gαi2 can outcompete Gαs for interaction with the β2-AR.

Although Gαi2 is considered to operate in opposition to Gαs, the inhibitory effects of over-expressing wild-type Gαi2 in muscle fibres described herein contrast with studies that documented protein accretion and cell growth after transducing myogenic cells with a constitutively active Gαi2Q205L mutant35. Global embryonic knock-out of Gαi2 produces mice with muscles of reduced myofibre size, although the animals also suffer from a lethal intestinal phenotype and immune cell defects that likely compromise interpretation of the muscle attributes37,38. Stronger evidence from cell culture studies supports a role for Gαi2 in guiding the proliferation and differentiation of myogenic progenitors35,37. While the mechanisms by which Gαi2Q205L promotes cell proliferation and recruitment lie outside the scope of the present study, the differences in effects of Gαi2Q205L reported elsewhere versus the effects of wild-type Gαi2 reported here appear to be attributed at least in part to differential actions within myogenic progenitor cells versus muscle fibres. Additionally, it cannot yet be ruled out that the Gαi2Q205L mutant isoform does not exert different effects on downstream signalling targets or is affected differently by feedback mechanisms.

Although the GNAS gene encodes for the GαsL G-protein in skeletal muscle, alternate Gαs transcript variants are encoded by GNAS in other cell types. As the predominantly neuroendocrine GαsXL variant39 has been reported to stimulate increased cAMP activity when compared with GαsL26,27, we reasoned that expressing GαsXL in muscle fibres may cause a hypertrophic response in skeletal muscle. Supporting this hypothesis, we found that muscles treated with AAV:GαsXL demonstrated a significant hypertrophic response with effects comparable to those achieved by treating muscles with either AAV:β2-AR or formoterol. Muscles treated with AAV:GαsXL exhibited an increased proportion of myofibres expressing the type IIa myosin heavy chain isoform, whereas no such effect was noted in muscles receiving AAV:β2-AR. These findings lend support to the idea that the two vector-based interventions have differing effects upon the physiological properties of treated skeletal muscles. The marked muscle hypertrophy with administration of AAV:GαsXL was recapitulated in mice lacking functional β1- and β2-ARs, which do not exhibit an anabolic response when administered anabolic β-agonists40. These results demonstrate that expression of GαsXL in skeletal musculature confers anabolic adaptations that are not dependent on active β1- and β2-ARs. It is not clear whether the observed muscle hypertrophy is a product of GαsXL possessing constitutive activity, or whether GαsXL proteins may be activated by other GPCRs in muscle fibres. Other receptors in muscle that could function as activators of ectopically expressed GαsXL include Fzd7 (previously implicated in regulation of myogenic cells41) and PTH1 (which promotes GαsXL activation in other tissues42,43). Collectively, these findings highlight fascinating aspects of how G proteins can modulate muscle attributes and support the rationale for further study.

In summary, this study presents the first demonstration that treatment of mammalian skeletal muscle fibres with recombinant AAV vectors expressing the β2-AR or GαsXL promote changes in protein turnover that favour myofibre hypertrophy. These proof-of-concept studies focused on manipulating β-adrenergic signalling in individual limb muscles and demonstrate the feasibility of stimulating anabolic signalling via the β2-AR signalling pathway without administering β2-AR agonists. The findings provide important insight into GPCR signalling in skeletal muscle, with implications for developing novel interventions for muscle wasting conditions. Given the uncertainties regarding the long-term administration of potent β2-AR agonists to patients, developing new strategies by which to promote anabolic β2-AR signalling in skeletal muscle without using β2-AR agonists warrants deeper investigation. This includes systemic administration of AAV vectors to achieve body-wide transduction of skeletal muscles. The findings reported here provide valuable insight into a new intervention concept, upon which such studies could be developed. Comprehensively investigating the consequences of muscle-directed gene delivery in mouse models of muscle wasting will help to determine the therapeutic potential of this novel strategy, including effects on muscle functionality and other organ systems.

Methods and Materials

All reagents were purchased from Sigma-Aldrich unless otherwise stated.

Animal Experiments

In vivo procedures were conducted in accordance with the relevant codes of practice for the care and use of animals for scientific purposes (National Institute of Health, 1985 and the National Health & Medical Research Council of Australia 2013). All experimental protocols were approved by the Alfred Medical and Education Precinct Animal Ethics Committee (AMREP AEC). All surgical procedures were performed under inhalation of isoflurane in medical oxygen with post-operative analgesia. Eight to 10 week old, male, C57Bl/6 and β12 mutant (β12mut) mice were used for all experiments. Animals were fed standard chow diets with access to drinking water ad libitum while housed under a 12-hour light dark cycle. β12mut mice were sourced and bred as described previously28. Doses of AAV:β2-AR, AAV:Gαi2, AAV:GαsL (1 × 1010 vg) and AAV:GαsXL (1 × 109 vg) vectors (identified from preliminary dose-optimisation experiments) were diluted in 30 μl of Hank’s buffered saline solution (HBSS) and directly injected into the TA muscle. Control injections consisted of the administration of a viral vector lacking a functional gene into the contralateral limb. For systemic β-agonist treatments, intraperitoneal injections of formoterol at 100 μg/kg or saline were administered daily for 28 days. Rapamycin (ApexBio) was dissolved in DMSO to a stock concentration of 10 mg/ml and a working concentration of rapamycin was formulated in a solution of 0.1% carboxymethylcellulose and 0.125% polysorbate-80. Mice received 2 mg/kg of rapamycin one day before and at the time of AAV:β2-AR administration by intraperitoneal injection. Mice were treated daily until experimental endpoint. For puromycin administration, mice received 0.04 μmol/g of puromycin (Life Technologies) via intraperitoneal injection exactly 30 min before experimental endpoint. Experimental endpoints were 28 days post viral vector administration unless indicated otherwise. Mice were humanely killed via cervical dislocation and the muscles rapidly excised and weighed before subsequent processing.


All antibodies were purchased from Cell Signaling Technologies and used at a dilution of 1:1000, except anti-puromycin and anti-laminin B2 (Millipore) which were used at 1:5000 and 1:250 respectively, anti-β2-AR (MBL) 1:500 and anti-GAPDH (Santa Cruz Biotechnology) 1:10000.

Recombinant AAV vector design and production

Traditional cloning techniques were used to generate cDNA constructs encoding Adrb2 (β2-AR), Gnai2 (Gαi2), GnasL (GαsL) and GnasXL (GαsXL) (synthesized by GenScript) which were cloned into an AAV expression plasmid consisting of a cytomegalovirus (CMV) promoter and SV40 poly-A region flanked by AAV2 terminal repeats. The Gαi2, GαsL and GαsXL cDNA construct also included a flag-tag coding region at the 5′ end of the coding sequences. Viral vector production was performed as described previously21. Briefly, HEK-293 cells were plated at a density of 3.2–3.8 × 106 cells on a 10 cm culture dish, 8–16 hours before transfection with 10 μg of a vector genome-containing plasmid and 20 μg of the packaging/helper plasmid pDGM6 by calcium phosphate precipitation. At 72 hours post transfection, the medium and cells were collected and homogenized through a microfluidizer (Microfluidics) before 0.22 μm clarification (Millipore). Purification of viral particles from crude lysates was performed using affinity chromatography over a heparin affinity column (HiTrap, Amersham) and ultracentrifugation overnight prior to re-suspension in sterile physiological Ringer’s solution. The purified vector preparations were titered with a customized sequence-specific quantitative PCR-based reaction (Life Technologies).

Western blotting

Muscles were homogenized in NP-40 lysis buffer containing protease and phosphatase inhibitor cocktails. Lysates were centrifuged at 15,000 g for 20 min at 4 °C, protein concentration was determined using a BCA protein assay kit (Thermo Scientific) and samples denatured for 5 min at 95 °C. Protein fractions were resolved by SDS-PAGE using pre-cast 4–12% Bis-Tris gels (Life Technologies), blotted onto nitrocellulose membranes (BioRad) and incubated with the appropriate primary antibody and detected as described previously44. Quantification of labelled western blots was performed using ImageJ pixel analysis (NIH Image software) and data normalized to corresponding GAPDH controls.

Histological analysis

Harvested muscles were embedded in optimum cutting temperature (OCT) cryoprotectant (Sakura Finetek) and frozen in liquid nitrogen-cooled isopentane. Frozen samples were cryosectioned at 10 μm thickness using a Leica CM1950 cryostat. Cross-sections were fixed in room temperature methanol and stained with hematoxylin and eosin as described previously44. Stained sections of muscles were examined using a light microscope with digital camera (BX-50, Olympus), to capture images analysed for muscle fibre morphology. Minimum Feret’s diameter of myofibres was quantified using ImageJ software analysis. Up to eight fields of view were captured from the same locations within each TA muscle and contrast adjusted to gate fibres based on numerical threshold, >200 myofibres were measured per muscle. Histochemical estimation of SDH activity and immunolabelling of the type-IIa myosin heavy chain isoform was performed on 10 μm thick cryosections of harvested TA muscles as previously described45. Images were captured (Axio Imager D1 microscope, Carl Zeiss). SDH activity was estimated by capturing four 100x magnification brightfield images per TA muscle and quantifying pixel density for each muscle fibre within the identified fields via ImageJ software analysis. Myosin type IIa positive fibres were counted and expressed relative to total number of myofibres counted per section (>600 fibres samples per muscle).

Immunofluorescence Microscopy

OCT-frozen TA samples were cryosectioned at 8 μm thickness, fixed in methanol, washed in potassium phosphate buffered saline (KPBS) containing gelatin and blocked in a solution consisting of Tween-20, BSA, gelatin and KPBS. The sections were incubated in anti-laminin B2 and anti-β2-AR primary antibodies overnight at 4 °C. Alexa-Fluor-488 and -594 secondary goat antibodies (Life Technologies) were used to detect β2-AR and laminin B2 primary antibodies respectively, followed by 3 min incubation in DAPI nuclear stain (Life Technologies) and mounting in HardSet Vectashield (Vector Laboratories). Images were captured using a BX61 light microscope (Olympus).

Statistical Analysis

All data are represented as the mean ± SEM. A paired Student’s t-test was used for comparisons between two conditions. Two-way analysis of variance (ANOVA) was used to measure statistical differences between multiple conditions with Tukey’s post hoc analysis for specific group comparisons. All significant differences are reported with p < 0.05.

Additional Information

How to cite this article: Hagg, A. et al. Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size. Sci. Rep. 6, 23042; doi: 10.1038/srep23042 (2016).


  1. Premont, R. T. & Gainetdinov, R. R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 69, 511–534 (2007).

  2. Dror, R. O. et al. Activation mechanism of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 108, 18684–18689 (2011).

  3. Ryall, J. G., Church, J. E. & Lynch, G. S. Novel role for β-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin. Exp. Pharmacol. Physiol. 37, 397–401 (2010).

  4. Daaka, Y., Luttrell, L. M. & Lefkowitz, R. J. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88–91 (1997).

  5. Pearen, M. A., Ryall, J. G., Lynch, G. S. & Muscat, G. E. Expression profiling of skeletal muscle following acute and chronic β2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 10, 448 (2009).

  6. Ryall, J. G., Plant, D. R., Gregorevic, P., Sillence, M. N. & Lynch, G. S. β2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J. Physiol. (Lond.) 555, 175–188 (2004).

  7. Toledo, M. et al. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J. Cachexia Sarcopenia Muscle 5, 315–320 (2014).

  8. Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013 (2001).

  9. Kline, W. O., Panaro, F. J., Yang, H. & Bodine, S. C. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J. Appl. Physiol. 102, 740–747 (2007).

  10. Gonçalves, D. A. et al. Mechanisms involved in 3′, 5′-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle. Endocrinology 150, 5395–5404 (2009).

  11. Joassard, O. R. et al. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle. Int. J. Biochem. Cell Biol. 45, 2444–2455 (2013).

  12. Koopman, R. et al. Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β-adrenoceptor stimulation in mice. J. Physiol. (Lond.) 588, 4811–4823 (2010).

  13. Maltin, C. A. et al. Inhibition and reversal of denervation-induced atrophy by the β-agonist growth promoter, clenbuterol. Biosci. Rep. 6, 811–818 (1986).

  14. Jiang, G. L. et al. Randomized, double-blind and placebo-controlled trial of clenbuterol in denervated muscle atrophy. ISRN Pharmaceut. 2011, 981254 (2011).

  15. Harcourt, L. J., Schertzer, J. D., Ryall, J. G. & Lynch, G. S. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromus. Dis. 17, 47–55 (2007).

  16. Kissel, J. T. et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 50, 1402–1406 (1998).

  17. Skura, C. L., Fowler, E. G., Wetzel, G. T., Graves, M. & Spencer, M. J. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70, 137–143 (2008).

  18. Ryall, J. G., Schertzer, J. D. & Lynch, G. S. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J. Gerontol. A. Biol. Sci. Med. Sci. 62, 813–823 (2007).

  19. Costelli, P. et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a β2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J. Clin. Invest. 95, 2367–2372 (1995).

  20. Greig, C. A. et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support. Care Cancer 22, 1269–1275 (2014).

  21. Blankinship, M. J. et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10, 671–678 (2004).

  22. Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828–834 (2004).

  23. Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192–201 (2015).

  24. Buchlis, G. et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119, 3038–3041 (2012).

  25. Goodman, C. A. et al. Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. FASEB J. 25, 1028–1039 (2011).

  26. Linglart, A. et al. Coding GNAS mutations leading to hormone resistance impair in vitro agonist- and cholera toxin-induced adenosine cyclic 3′,5′-monophosphate formation mediated by human XLαs. Endocrinology 147, 2253–2262 (2006).

  27. Mariot, V. et al. Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Bone 48, 312–320 (2011).

  28. Church, J. E. et al. Functional β-adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation. PLoS One 9, e101379 (2014).

  29. Rohrer, D. K., Chruscinski, A., Schauble, E. H., Bernstein, D. & Kobilka, B. K. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J. Biol. Chem. 274, 16701–16708 (1999).

  30. Burniston, J. G. et al. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J. Appl. Physiol. 93, 1824–1832 (2002).

  31. Duncan, N. D., Williams, D. A. & Lynch, G. S. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin. Sci. 98, 339–347 (2000).

  32. Gregorevic, P., Ryall, J. G., Plant, D. R., Sillence, M. N. & Lynch, G. S. Chronic β-agonist administration affects cardiac function of adult but not old rats, independent of β-adrenoceptor density. Am. J. Physiol. Heart Circ. Physiol. 289, H344–349 (2005).

  33. Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457–1467 (2007).

  34. Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320–329 (2007).

  35. Minetti, G. C. et al. Gαi2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation and muscle regeneration. Sci. Signaling 4, ra80 (2011).

  36. Chen, M. et al. Gsα deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching and glucose intolerance without insulin resistance or deficiency. Am. J. Physiol. Cell Physiol. 296, C930–940 (2009).

  37. Minetti, G. C. et al. Gαi2 signaling is required for skeletal muscle growth, regeneration and satellite cell proliferation and differentiation. Mol. Cell. Biol. 34, 619–630 (2014).

  38. Rudolph, U. et al. Ulcerative colitis and adenocarcinoma of the colon in Gαi2-deficient mice. Nat. Genet. 10, 143–150. (1995).

  39. Weinstein, L. S., Xie, T., Zhang, Q. H. & Chen, M. Studies of the regulation and function of the Gsα gene Gnas using gene targeting technology. Pharmacol. Ther. 115, 271–291 (2007).

  40. Hinkle, R. T. et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β2-adrenergic receptor. Muscle Nerve 25, 729–734 (2002).

  41. von Maltzahn, J., Bentzinger, C. F. & Rudnicki, M. A. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat. Cell Biol. 14, 186–191 (2012).

  42. He, Q., Zhu, Y., Corbin, B. A., Plagge, A. & Bastepe, M. The G protein α subunit variant XLαs promotes inositol 1,4,5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo. Sci Signal 8, ra84 (2015).

  43. Kimura, S. & Yoshioka, K. Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation. Sci. Rep. 4, 5066 (2014).

  44. Winbanks, C. E. et al. TGF-β regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J. Biol. Chem. 286, 13805–13814 (2011).

  45. Johnston, A. J. et al. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell 162, 1365–1378 (2015).

Download references


The authors thank Dr Catherine E. Winbanks and Dr Lucy Cassar (previously Baker IDI Heart and Diabetes Institute), Mr Timur Naim (Department of Physiology, University of Melbourne) and Mr Stephen Cody and Dr Iska Carmichael (Micro Imaging facility, AMREP campus) for technical guidance. This work was supported by Project Grant funding (509313; 1026231 awarded to G.S.L. and P.G.) from the National Health and Medical Research Council (NHMRC). P.G. is supported by a NHMRC Career Development Fellowship (1046782) and previously, a Senior Research Fellowship sponsored by Pfizer Australia. The Baker IDI Heart & Diabetes Institute is supported in part by the Operational Infrastructure Support Program of the Victorian Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information




Designed the studies: A.H., G.S.L., P.G. Undertook the experimental work: A.H., T.D.C., R.E.T., H.Q., P.G. Analysed the data A.H., T.D.C., R.E.T., G.S.L., P.G. Contributed to figure and manuscript preparation: A.H., T.D.C., G.S.L., P.G.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Electronic supplementary material

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hagg, A., Colgan, T., Thomson, R. et al. Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size. Sci Rep 6, 23042 (2016).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.